Have the markets turned the corner? Maybe not – but maybe so, at least for the short term. Despite rising inflation in the States, and Russia’s continuing war against Ukraine, high prices for oil, and disruptions in the global commodity markets, Wall Street just finished its best week since November of 2020. Between March 14 and March 18, the S&P 500 rose ~6%, while the NASDAQ was up ~9%. Investors were clearly in a buying mood, and the indexes reflected it.
However, some Wall Street pros are understandably concerned that the market is still vulnerable. In this environment, investors are going to gravitate toward stocks that have proven records of strong share price appreciation. While we all know that past performance won’t guarantee future results, the best place to start looking for tomorrow’s high-growth stocks is among yesterday’s winners.
Using TipRanks’ database, we’ve found three ‘monster growth’ names that saw hefty gains over the past 12 months. Each name is well-loved by Wall Street analysts, and has received enough bullish calls to score a “Strong Buy” consensus rating.
Golar LNG Limited (GLNG)
We’ll start in the energy industry, where Golar LNG has exploited some economic quirks of the natural gas industry to become a leader in the liquified natural gas sector. The company specializes in the building and operation of floating natural gas liquefaction facilities, a niche that makes it possible to exploit previously non-economic gas reserves. Natural gas must be liquefied for safe long-distance transport, and Golar brings the liquefaction facilities to the gas fields – and can move those facilities when necessary. Golar boasts that its floating gas liquefaction fleet can operation at a lower cost than land-based facilities.
High energy prices, and particularly rising prices for natural gas on the global market, has been good for Golar. The company has seen its share price rise 70% so far this year.
A quick look at the company’s earnings will show the extent of the growth, and the potential. In 4Q21, Golar showed $93.5 million in EBITDA, up from $78 million in the year-ago quarter. Sequentially, the gain was higher; Q3’s result had been $74.5 million.
BTIG analyst Gregory Lewis sees Golar in a strong position to gain additional business, writing: “We believe we are on the cusp of a multi-year run in LNG project FIDs (Final Investment Decision) as we expect natural gas to serve as a bridge fuel as the world shifts to renewable energy over the next few decades. And more importantly… Golar has a much improved capital structure (~$500M in current liquidity to go after its next flexible Floating LNG (FLNG) project which includes ~$250M in cash), an existing base of LNG assets which could be FLNG conversion projects, and FLNG solutions, which we think positions the company to win multiple FLNG projects over the next two years.”
These comments support Lewis’s Buy rating, while his $30 price target on GLNG stock implies ~43% upside for the coming year. (To watch Lewis’ track record, click here)
Overall, Golar’s Strong Buy analyst consensus rating is based on 8 recent stock reviews, that include 6 to Buy and 2 to Hold. The shares are priced at $21.02, and their $22.81 average price target indicates an 8.5% upside from that level. (See GLNG stock analysis on TipRanks)
Matador Resources Company (MTDR)
Sticking with the energy sector, we’ll turn our view to Matador Resources. This company engages in hydrocarbon exploration, development, and extraction, focusing on unconventional plays in the North American oil and natural gas industries. Matador has is primary operations in the Wolfcamp and Bone Spring plays the Texas-New Mexico Delaware Basin, with additional assets in Northwest Louisiana.
Matador’s operations are generating cash as well as hydrocarbons. The company reported $334.5 million in cash from operations for 4Q21, up 15% from Q3, and an even stronger 112% year-over-year. This total included $119.3 million in adjusted free cash flow, nearly double the year-ago quarter’s $60.7 million.
The steady growth in cash flow prompted Matador to increase its quarterly dividend this past fall, and to maintain the higher payment this month. The last dividend, paid out on March 14, was for 5 cents per common share. This annualizes to 20 cents, and gives a modest yield 0f 0.3%. The key point here is not the yield, but the combination of management’s statement of intent to increase the returns to shareholders along with the company’s strong cash flow generation. It’s important to note here that MTDR shares have gained 118% in the past 12 months.
Neil Dingmann, 5-star analyst from Truist, writes of Matador: “We believe Matador has done a notable job of creating value in its ten year existence... By our estimates, the company continues to be set up for solid upcoming production/cash flow/stock price growth despite the strong share performance already seen in the past several months. We have high confidence of continued strong well performance in the ~70 wells to be turned to sales this year given the continued operational efficiencies/outperformance previously demonstrated.”
Dingmann’s bullish stance comes with a Buy rating on the stock, while his $68 price target suggests Matador has room for ~29% upside growth by the end of this year. (To watch Dingmann’s track record, click here)
There are seven recent reviews of Matador shares on record and they all agree that this is one to buy, making the Strong Buy consensus unanimous. The stock is selling for $52.81 and its $62 average price target implies ~17% one-year upside. (See MTDR stock analysis on TipRanks)
Intra-Cellular Therapies (ITCI)
Let’s shift gears now, and turn to the biopharmaceutical industry. Intra-Cellular Therapies is a clinical- and commercial-stage research company developing new treatments for mental health disorders in adults. This is a field with, in the jargon, ‘high unmet medical needs.’ Mental health diseases place a heavy burden on both patients and caregivers, and treatments currently available suffer from both poor success rates, high con-compliance rates with treatment, dangerous or undesirable side effects – or all of that combined. This gives Intra-Cellular an opening, if it can get a more effective drug to market.
The company is on the cusp of that. In December of last year, the FDA approved ITCI’s leading product, lumateperone (branded as Caplyta) for the treatment of bi-polar depression in adults. This was an important label extension for Caplyta, which has already been approved in December of 2019 as a treatment for adult schizophrenia. Having a drug on the market is the Holy Grail for biopharma companies, and Intra-Cellular has seen a steady – and steadily increasing – revenue stream from Caplyta since its initial approval.
In the last quarter reported, 4Q21, Intra-Cellular showed $25.7 million in top-line revenues. This was a 106% jump from the year-ago quarter, and marks the 7th straight quarter of revenue gains since Caplyta went on the market. Shares in ITCI reflect this revenue growth – the stock is up 70% since this time last year.
The company is following up on its current success with lumateperone, and has additional clinical trials underway. The drug is being evaluated in a pair of Phase 3 double-blind placebo controlled studies as an adjunctive treatment for major depressive disorder. In addition, Intra-Cellular has three other drug candidates in earlier-stage clinical trials, for conditions ranging from Alzheimer’s and dementia to Parkinson’s and opioid abuse.
Covering ITCI for Jefferies, analyst Andrew Tsai writes: “In 2022, we think ITCI stock could break all-time highs despite a challenging tape, as Caplyta scripts are accelerating earlier (and perhaps even faster) than Street expectations… For SCZ/BPD, we can derive a valuation of $6-8B + (or $65-85/sh) by applying a 3-4x multiple to our above-cons $2B peak sales estimate, though this thinking is perhaps conservative and excludes the Phase II/III pipeline (which deserves credit). Bottom line, a healthy balance sheet (we est Q1 cash of $750M +), a strong narrative (clean story), and meaningful upside potential (SCZ/BPD plus pipeline optionality) drive scarcity value, leading us to think ITCI stock should continue outperforming this year.”
In line with this upbeat outlook, Tsai rates the stock a Buy, and his $90 price target implies an upside of 47% this year. (To watch Tsai’s track record, click here)
Tsai is hardly the only bull on this stock; ITCI has a unanimous Strong Buy consensus rating supported by 9 analyst reviews. The average price target of $68.67 gives a 12% upside potential from the current share price of $61.05. (See ITCI stock analysis on TipRanks)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.